Preview

Медицинский алфавит

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Доступ платный или только для Подписчиков

Новые стратегии диагностики и лечения болезни Альцгеймера: моноклональные антитела к бета-амилоиду

https://doi.org/10.33667/2078-5631-2019-1-2(377)-35-42

Полный текст:

Аннотация

Болезнь Альцгеймера (БА) - прогрессирующее нейродегенеративное заболевание, которое является наиболее распространенной причиной деменции. В настоящее время в мире насчитывается около 46,8 миллиона человек, страдающих БА. Считается, что число пациентов с БА удваивается почти каждые 20 лет, и все более остро стоит вопрос о своевременном лечении и продлении активной жизни данных пациентов. На сегодняшний день одобрены только пять препаратов для лечения БА, они включают ингибиторы холинэстеразы и антагонисты N-метилФ-аспартата рецепторов (мемантин). К сожалению, их применение обеспечивает временный и неполный симптоматический эффект, может сопровождаться побочными эффектами и не замедляет прогрессирование БА, поэтому крайне актуальна разработка лекарств для более эффективного лечения БА. Лабораторные и клинические исследования говорят о том, что в ближайшем будущем терапия БА станет более направленной на модификацию болезни и вероятно, что БА будет успешно лечиться еще до развития значительных когнитивных нарушений, на пресимптоматическом или доклиническом этапах. Главной терапевтической целью этих исследований является лечение патологического процесса (снижение β-амилоидоза или уменьшение образования нейрофибриллярных клубков) для предотвращения последующей нейродегенерации и возможного когнитивного снижения. В настоящее время, несмотря на всевозможные проблемы, иммунотерапия с введением моноклональных антител к β-амилоиду считается одним из наиболее перспективных подходов к уменьшению степени нейродегенерации.

Об авторах

А. А. Пилипович
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России
Россия


А. Б. Данилов
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава России
Россия


Список литературы

1. АН G-С, Guerchet M, Wu Y-T, Prince M, Prina M. Chapter 2: The global prevalence of dementia. In: Prince M, GuerchetM, Ali G-C Wu Y-T, Prina M, editors. The Global Impact of Dementia. An analysis of prevalence, incidence, cost and trends. London: Alzheimer’s Disease international (ADI); 20І5. p. 10-29.

2. Xiaoguang Du, Xinyi Wang 1 and Meiyu Geng. Alzheimer’s disease hypothesis and related Therapies. Du et al. Translational Neurodegeneration. 2018; 7: 2.

3. Емелин А. Ю. Новые критерии диагностики болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2011; 3 (4): 5-8.

4. Sperling R. A., Aisen P.S., Beckett L. A., Bennett D. A., Craft S., Fagan A. M., Iwatsubo T., Jack C. R., Kaye J., Montine T. J., Park D. C., Reiman E. M., Rowe C. C., Siemer S. E., Stern Y., Yaffe K., Carrillo M. C., Thies B., Morrison-Bogorad M., Wagster M. V., Phelps C. H. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimets Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement. 20ІІ; 7 (3): 280-292.

5. Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science. 1992; 256 (5054): 184-185.

6. Musiek ES, Holtzman DM. Three dimensions of the amyloid hypothesis: time, space and ‘wingmen’. NatNeurosci. 2015; 18 (6): 800-806.

7. Wang J, Gu BJ, Masters CL, Wang YJ. A systemic view of Alzheimer disease - insights from amyloidbeta metabolism beyond the brain. Nat Rev Neurol. 2017; 13 (10): 612-623.

8. Bennett D. A., Schneider J.A., Arvanitakis Z., Kelly JF, Aggarwal NT, Shah RC, Wilson RS. Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 2006; 66 (12): 1837-1844.

9. Cummings J, Aisen PS, DuBois B, Frölich L, Jack CR Jr, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P. Drug development in Alzheimer’s disease: the path to 2025. Alzheimers Res Ther. 2016; 8: 39.

10. Vassar R, Citron M. Abeta-generating enzymes: recent advances in beta- and gamma-secretase research. Neuron. 2000; 27 (3): 419-22.

11. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H. Notch/ gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature. 2005; 435 (7044): 959-963.

12. Olry A, Chastagner P, Israël A, Brou C. Generation and characterization of mutant cell lines defective in gamma-secretase processing of notch and amyloid precursor protein. J Biol Chem. 2005; 280 (31): 28564-71.

13. Tarassishin L, Yin YI, Bassit B, Li YM. Processing of notch and amyloid precursor protein by gamma-secretase is spatially distinct. Proc Natl Acad Sci U S A. 2004; 101 (49): 17050-17055.

14. Klaver DW, Wilce MC, Cui H, Hung AC, Gasperini R, Foa L, Small DH. Is BACE 1 a suitable therapeutic target for the treatment of Alzheimer’s disease? Current strategies and future directions. Biol Chem. 2010; 391 (8): 849-59.

15. Abramov E, Dolev I, Fogel H, Ciccotosto GD, Ruff E, Slutsky I. Amyloid-beta as a positive endogenous regulator of release probability at hippocampal synapses. Nat Neurosci. 2009; 12 (12): 1567-1576.

16. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, Eisner L Kirby L, Rovira MB, Forette F, Orgogozo JM. Clinical effects of Abeta immunization (AN 1792) in patients with AD in AN interrupted trial. Neurology. 2005;64 (9): 1553-1562.

17. Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, Donoghue S. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN 1792) in patients with AD. Neurology. 2005; 64 (1): 94-101.

18. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, Jones RW, Bullock R, Love S, Neal JW, Zotova E, Nicoll JA. Long-term effects of Abeta42 immunisation in Alzheimer’s disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008; 372 (9634): 216-23.

19. Arai H, Suzuki H, Yoshiyama T: Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer’s disease: Results from two phase 2 studies. Curr Alzheimer Res 2015; 12: 242-254.

20. Pasquier F, Sadowsky C, Holstein A, Leterme Gle P, Peng Y, Jackson N, et al. Two phase 2 multiple ascending-dose studies of vanutide cridificar (ACC-001) and QS-21 adjuvant in mild-tomoderate Alzheimer’s disease. J Alzheimer Dis 2016; 51: 1131-1143.

21. van Dyck CH, Sadowsky C, Le Prince Leterme G, Booth K, Peng Y, et al. Vanutide cridificar (ACC-001) and QS-21 adjuvant in individuals with early Alzheimer’s disease: Amyloid imaging positron emission tomography and safety results from a phase 2 study. J Prev Alzheimers Dis 2016; 3: 75-84.

22. Farlow MR, Andreasen N, Riviere ME, Vostiar I, Vitaliti A, Sovago J, et al. Long-term treatment with active Abeta immunotherapy with CAD 106 in mild Alzheimer’s disease. Alzheimers Res Ther 2015: 7: 23.

23. Winblad B, Andreasen N, Minthon L, Floesser A, Imbert G, Dumortier T, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD 106 in patients with Alzheimer’s disease: Randomised, double-blind, placebo-controlled, first-inhuman study. Lancet Neurol (2012): 11: 597-604.

24. Montoliu-Gaya L, Villegas S Abeta-Immunotherapeutic strategies: a wide range of approaches for Alzheimer’s disease treatment. Expert Rev Mol Med 2016; 18: e13.

25. Sarazin M, Dorothee G, de Souza LC, Aucouturier P Immunotherapy in Alzheimer’s disease: Do we have all the pieces of the puzzle? Biol Psychiatry 2013; 74: 329-332.

26. Reiman EM, Langbaum JB, Fleisher AS, Caselli RJ, Chen K, Ayutyanont N, et al. Alzheimer’s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis. 2011: 26 (suppl 3): 321-329.

27. Laskowitz DT, Kolls BJ. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2010; 74 (24): 2026.

28. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, Sabbagh M, Honig LS, Doody R, van Dyck CH, Mulnard R, Barakos J, Gregg KM, Liu E, Lieberburg I, Schenk D, Black R, Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology. 2009;73 (24): 2061-2070.

29. Cummings J, Cho W, Ward M, Friesenhahn M, Brunstein F, Honigberg L, et al. (2014): A randomized, double-blind, placebo-controlled phase 2 study to evaluate the efficacy and safety of crenezumab in patients with mild to moderate Alzheimer’s disease. Presented at Alzheimer’s Association International Conference (AAIC), Copenhagen, Denmark, July 16, 2014.

30. Salloway S, Cho W, Clayton D, Honigberg L, Rabe C, Friesenhahn M, et al. (2014): Amyloid PET imaging results from a study to evaluate the impact of crenezumab on fibrillar amyloid in patients with mild-tomoderate Alzheimer’s disease. Presented at Clinical Trials on Alzheimer’s Disease (CTAD), Philadelphia, PA, November 20, 2014.

31. Honigberg L, Clayton D, Cho W, Rabe C, Friesenhahn M, Ward M, et al. (2014): Biomarker results from the crenezumab anti-Ab phase 2 biomarker trial. Presented at Clinical Trials on Alzheimer’s Disease (CTAD), Philadelphia, PA, November 20-22, 2014.

32. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. (2014): Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med 370:311-321.

33. Farlow M, Arnold SE, van Dyck CH, Aisen PS, Snider BJ, Porsteinsson AP, et al. (2012): Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement 8: 261-271.

34. Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study. Clin Neuropharmacol. 2013; 36 (1): 14-23.

35. Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, McCush F, Alvey C, Kupiec JW, Bednar MM. Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease. Clin Neuropharmacol. 2013; 36 (1): 8-13.

36. La Porte SL, Bollini SS, Lanz TA, Abdiche YN, Rusnak AS, Ho WH, Kobayashi D, Harrabi O, Pappas D, Mina EW, Milici AJ, Kawabe TT, Bales K, Lin JC, Pons J. Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012;421 (4-5): 525-536.

37. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks DJ, et al. (2012): Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 69: 198-207.

38. Lasser R, Ostrowitzki S, Scheltens P, Boada M, Dubois B, Dorflinger E, et al. (2015): Efficacy and safety of gantenerumab in prodromal Alzheimer’s disease: Results from scarlet road-a global, multicenter trial. Alzheimers Dement 11 (suppl): 331-332.

39. Logovinsky V, Satlin A, Lai R, Swanson C, Kaplow J, Osswald G, et al. (2016): Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Abeta antibody. Alzheimers Res Ther 8: 14.

40. Sevigny J, Chiao P, Bussière T, Weinreb PH, Williams L, MaierM, Dunstan R, Salloway S, Chen T, Ling Y, O'Gorman J, Qian F, Arastu M, LiM, Chollate S, Brennan MS, Quintero-Monzon O, Scannevin RH, Arnold HM, Engber T, Rhodes K, Ferrero J, Hang Y, Mikulskis A, Grimm J, Hock C, Nitsch RM, Sandrock A. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature. 2016; 537 (7618): 50-56.

41. Carlson C, Siemers E, Hake A, Case M, Hayduk R, Suhy J, Oh J, Barakos J. Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease. Alzheimers Dement (Amst). 2016; 2: 75-85.

42. Salloway S, Sperling R, Keren R, Porsteinsson AP, van Dyck CH, Tariot PN, Gilman S, Arnold D, Abushakra S, Hernandez C, Crans G, Liang E, Quinn G, Bairu M, Pastrak A, Cedarbaum JM. A phase 2 randomized trial of ELND 005, scyllo-inositol, in mild to moderate Alzheimer disease. Neurology. 2011;77 (13): 1253-1262.

43. Aisen PS, Gauthier S, Ferris SH, Saumier D, Haine D, Garceau D, Duong A, Suhy J, Oh J, Lau WC, Sampalis J. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase study). Arch Med Sci. 2011;7 (1): 102-111.

44. Greenberg SM, Rosand J, Schneider AT, Creed Pettigrew L Gandy SE, Rovner B, Fitzsimmons BF, Smith EE, Edip Gurol M, Schwab K, Laurin J, Garceau D. A phase 2 study of tramiprosate for cerebral amyloid angiopathy. Alzheimer Dis Assoc Disord. 2006;20 (4): 269-274.

45. Gervais F, Paquette J, Morissette C, Krzywkowski P, Yu M, Azzi M, Lacombe D, Kong X, Aman A, Laurin J, Szarek WA, Tremblay P. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007; 28 (4): 537-547.

46. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011; 10 (9): 698-712.

47. Nie Q, Du XG, Geng MY. Small molecule inhibitors of amyloid beta peptide aggregation as a potential therapeutic strategy for Alzheimer's disease. Acta Pharmacol Sin. 2011; 32 (5): 545-551.

48. Karran E. Recent trial shows that solanezumab has disease modifying effects. BMJ. 2015; 351: h4528.

49. Siemers ER, Sundell KL, Carlson C, Case M, Sethuraman G, Liu-Seifert H, Dowsett SA, Pontecorvo MJ, Dean RA, Demattos R. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer's disease patients. Alzheimers Dement. 2016; 12 (2): 110-120.

50. Barrera-Ocampo A, Lopera F. Amyloid-beta immunotherapy: the hope for Alzheimer disease? Colomb Med (Cali). 2016; 47 (4): 203-212.

51. Li L Sengupta A, Haque N, Grundkelqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer’s type abnormal hyperphosphorylation of tau and assotiated neurodegeneration. FEBS Letters. 2004; 566 (1-3): 261-269.

52. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. The Cochrane database of systematic reviews. 2006; 2: CD 003154

53. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141 (11): 1356-1364.

54. Matsunaga S, Kishi T, Iwata N. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis. PLoS One. 2015; 10 (4): e0123289.

55. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. The New England journal of medicine. 2003; 348 (14): 1333-1341.

56. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2006; 14 (8): 704-715

57. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. Journal of Alzheimer's disease: JAD. 2007; 11 (4): 471-479.

58. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E, Memantine MEMMDSG. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer disease and associated disorders. 2007; 21 (2): 136-143.

59. Schmidt R, Ropele S, Pendl B, Ofner P, Enzinger C, Schmidt H, et al. Longitudinal multimodal imaging in mild to moderate Alzheimer disease: a pilot study with memantine. Journal of neurology, neurosurgery, and psychiatry. 2008; 79 (12): 1312-1317.

60. Kitamura S, Homma A, Nakamura Y. Late phase II study of mementine hydrochloride, a new NMDA receptor antagonist, in pa tients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat. 2011; 22 (4): 453-463.

61. Nakamura Y, Homma A, Kitamura S, Yoshimura I. Phase IIIstudy of mementine hydrochloride, a new NMDA receptor antagonist, in patients with moderate to severe Alzheimer's disease. Jpn J Geriatr Psychiat. 2011; 22 (4): 464-І73.

62. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. The New England journal of medicine. 2012; 366 (10): 893-903.

63. Wang T, Huang Q, Reiman EM, Chen K, Li X, Li G, et al. Effects of memantine on clinical ratings, fluorodeoxyglucose positron emission tomography measurements, and cerebrospinal fluid assays in patients with moderate to severe Alzheimer dementia: a 24-week, randomized, clinical trial. J Сііп Psychopharmacol. 2013; 33 (5): 636-642.

64. Li L, Sengupta A, Haque N, Grundke-Iqbal I, Iqbal K. Memantine inhibits and reverses the Alzheimer’s type abnormal hyperphosphorylation of tau and assotiated neurodegeneration. FEBS Letters. 2004; 566 (1-3): 261-269.

65. Куташов В. А., Самсонов А. С. Комплаентность и качество терапии болезни Альцгеймера при приеме меманталя. РМЖ. 2014; 22: 1603-1605.

66. Ширяев О. Ю., Шаповалов Д. А., Полозова Т. М., Гончарова О. В., Кузнецова Н. А., Черенкова Е. В., Федорова Е. Ю. Сравнение эффективности и безопасности меманталя и оригинального препарата мемантин при легкой и умеренной деменции при болезни Альцгеймера. Журнал неврологии и психиатрии им. С. С. Корсакова. 2015; 115 (10): 56-61.


Для цитирования:


Пилипович А.А., Данилов А.Б. Новые стратегии диагностики и лечения болезни Альцгеймера: моноклональные антитела к бета-амилоиду. Медицинский алфавит. 2019;1(2):35-42. https://doi.org/10.33667/2078-5631-2019-1-2(377)-35-42

For citation:


Pilipovich A.A., Danilov A.B. New strategies for diagnosis and treatment of Alzheimer's disease: monoclonal antibodies to beta-amyloid. Medical alphabet. 2019;1(2):35-42. (In Russ.) https://doi.org/10.33667/2078-5631-2019-1-2(377)-35-42

Просмотров: 62


ISSN 2078-5631 (Print)